

CLINICAL ADVISORY COMMITTEE ESTABLISHED TO ADVANCE PHASE 2B DEVELOPMENT

Perth, Australia; 14 MAY 2026- Argenica Therapeutics Limited (ASX: AGN) (“Argenica” or the “Company”), a biotechnology company developing novel therapeutics to reduce brain tissue death after stroke and other acute neurological conditions, is pleased to announce the **establishment of a new Clinical Advisory Committee (CAC)** to assist with the advancement of its Phase 2b clinical trial of ARG-007 in acute ischaemic stroke (AIS).

The CAC brings together internationally recognised experts across stroke neurology, neurointervention, neuroimaging, neuroprotectant drug development, and clinical trial design, providing clinical and development expertise specific to stroke, as ARG-007 progresses into later stage clinical trial. The CAC will support the optimisation of trial design, including endpoints, patient selection and dosing strategy, to maximise the probability of clinical success in the planned Phase 2b study.

Clinical Advisory Committee Members:

- **Professor Geoffrey Donnan** – Professor of Neurology at the University of Melbourne, co-chair of the Australian Stroke Alliance and former President of the World Stroke Organization, with global leadership in stroke research and large-scale trials, including development of imaging-based approaches to guide patient selection.
- **Dr Tim Phillips** – Consultant interventional neuroradiologist at Sir Charles Gairdner, Fiona Stanley and Royal Perth Hospitals, with expertise in endovascular stroke treatment and reperfusion therapies. Leads the highest-volume interventional neuroradiology service in Australia and is Principal Investigator on 11 currently active clinical trials.
- **Professor Jeffrey Saver** – Vascular neurologist at the University of California Los Angeles (UCLA) and Director of the UCLA Stroke Center, internationally recognised for leadership in acute stroke treatment and major ischaemic stroke clinical trials, including contributions to neuroprotection, EVT management of LVO, patient selection and treatment decision-making through trial design and analysis.
- **Dr Michael Devlin** – Specialist neurologist and stroke physician at Princess Alexandra Hospital, Brisbane, with experience in acute stroke management and clinical trial conduct, including principal investigator experience in the Phase 2 trial and across multiple imaging-selected stroke trials large vessel occlusion.
- **Dr Taylor Kimberly** – Chief of Neurocritical Care at Mass General Brigham, Professor of Neurology at Harvard Medical School, with expertise in stroke imaging and

biomarker development, including quantitative imaging approaches to assess brain injury and support patient stratification, and co-principal investigator leadership in late-stage trials of a neuroprotectant in large hemispheric infarction.

- **Mr Tony Rolfe** – Consumer representative with over 40 years’ experience across Australian health policy and research systems, including senior roles at the NHMRC. Brings expertise in research ethics, consumer engagement and translation, alongside lived experience of stroke and leadership within the Stroke Foundation Consumer Council.

The CAC will be supported by Argenica’s non-executive Director, **Dr Mark Etherton** – Vascular neurologist, Former Director of the Massachusetts General Hospital Acute Stroke Service, Non-Executive Director of Argenica and Senior Medical Director at Takeda Pharmaceuticals, with expertise in stroke and neuroprotection trials and clinical drug development.

Dr Liz Dallimore, Managing Director of Argenica, commented: *“The appointment of this Clinical Advisory Committee represents an important step in advancing ARG-007 into a Phase 2b clinical trial. The Committee brings deep expertise in moderate-to-severe stroke, imaging-based patient selection and late-stage clinical development, which will be critical in optimising trial design and execution. We are focused on maximising the probability of success as we progress ARG-007 towards the next stage of development.”*

This announcement has been approved for release by the Board of Argenica

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica Therapeutics Limited (ASX: AGN) is a clinical-stage biotechnology company developing innovative neuroprotective therapeutics to improve outcomes for patients following stroke and other acute neurological injuries. The Company’s lead drug candidate, ARG-007, is designed to protect vulnerable brain tissue by reducing cell death and limiting secondary damage after an ischemic event. With a strong scientific foundation and a clear clinical development pathway, Argenica is focused on advancing novel treatments that have the potential to significantly improve patient recovery and transform the standard of care in acute neurology.